Boston Scientific's MANDARIN Trial Compares TheraSphere Against Chemoembolization in Chinese Liver Cancer Patients
核心洞察
Boston Scientific's MANDARIN (S6371) trial compares TheraSphere glass bead radioembolization against conventional artery-based chemoembolization in Chinese liver cancer patients who cannot undergo surgery.
The interventional, randomized, parallel-design study with no blinding is now listed as completed, with its most recent update filed on 10 August 2026.
Positive results could strengthen TheraSphere's adoption and pricing power in China and other Asian markets, where interventional oncology competition is intense.
Boston Scientific (BSX) has provided an update on its MANDARIN (S6371) clinical study, which evaluates liver cancer patients in China who cannot undergo surgery. The trial's official objective is to compare how well TheraSphere glass beads perform versus a standard artery-based chemo method, and how safe each option is. The study targets a major local need and could shape treatment choices in a large, growing market.
Study Design and Treatment Arms
The MANDARIN study tests two treatments for liver tumors. The first is TheraSphere, tiny glass beads placed into the liver artery to deliver focused radiation. The second is conventional chemo given through the same artery, which uses drugs and blocking agents to cut blood supply to the tumor and expose it to medicine.
The trial is interventional and randomized, meaning patients are assigned by chance to one of the two treatments. It uses a parallel design, with each group following its own path, and no blinding, so doctors and patients know which treatment they receive. The main aim is to determine which approach offers better treatment outcomes and safety.
Trial Timeline and Status
The study was first submitted on 09 August 2021, marking the formal start of public tracking. It is now listed as completed, and the most recent update was filed on 10 August 2026, signaling that fresh information has been added. These dates matter because they show progress and help investors time how they react to new data.
Strategic Implications for the Liver Cancer Franchise
This update strengthens Boston Scientific's liver cancer franchise and could support sentiment around its oncology pipeline. If results show clear benefits for TheraSphere, it may improve pricing power and drive adoption in China and other Asian markets, where rivals in interventional oncology also push hard. Strong data can lift confidence in BSX, while weak signals may shift interest to competitors.
Parallel Dosimetry Study
Boston Scientific is separately launching a new post-approval study titled "A Post Approval Single-arm Study Evaluating Transarterial Radioembolization Treatment for Hepatocellular Carcinoma (搜索) Using Multicompartment Dosimetry Planning." The goal is to assess whether a new planning method for its liver cancer device can improve safety and tumor control in real-world use.
This dosimetry study focuses on TheraSphere, with the new method—called multicompartment dosimetry—aiming to push more radiation into the tumor while better protecting healthy liver tissue. It is an observational, single-arm, prospective study that tracks patients already set to receive TheraSphere, with no randomization, no control group, and no blinding. The study was first submitted on May 29, 2026, with the most recent update filed on June 22, 2026, and is listed as not yet recruiting.
For investors, this reinforces Boston Scientific's push to deepen evidence behind TheraSphere in liver cancer. Positive safety and effectiveness data could support broader adoption, improve pricing power, and strengthen BSX against competitors in liver-directed therapies. While the study is not yet enrolling and any commercial impact is medium to long term, it highlights ongoing innovation in BSX's oncology portfolio.